Digital & Innovation
Data is the biggest challenge, and opportunity, for MedTech
Digital & Innovation: Medical technology is increasingly shaping the future of healthcare. The sector is also a growing part of the Australian economy and a major export earner. Medical and pharmaceutical products, at over $8 billion, were Australia’s most valuable manufacturing export in 2020, according to life science healthcare fund, Brandon Capital.
But what are the trends shaping the future of MedTech? What are the challenges and opportunities that Australian companies face, and what has been the impact of the global pandemic?
COVID-19 has certainly changed the rules. Rapid deployment of technology and innovation, for example, are destined to become part of the new normal, as is increased use of data to inform healthcare decision making.
Looking beyond COVID, however, the MedTech sector must manage the exponential growth of both data volumes and the number of data sources that products must integrate with to be successful.
Data growth rates are higher in the healthcare sector than almost anywhere else. According to the IDC white paper, Data Age 2025, healthcare data is projected to grow faster than in manufacturing, financial services or media, experiencing a compound annual growth rate (CAGR) of 36% through to 2025.
Smart healthcare devices and point of care devices located in patients’ homes are just some of the drivers of this trend, with data captured from them allowing real-time monitoring of the patient’s condition.
This exponential data growth presents a major challenge for data scientists at medical device manufacturers, who often spend as little as 20% of their time on actual data analysis.
Interoperability a “stumbling block”
According to John Kelly, Regional Manager, MedTech for InterSystems, the bulk of data scientists’ time is spent tracking down, cleaning and reorganising huge volumes of data stored in multiple silos and in different formats and standards.
“Interoperability – in other words the ability of disparate software to exchange and make use of information – is key,” says Kelly. “Unfortunately, the lack of interoperability between systems has been a major stumbling block for innovation. We are investing a lot of effort into solving this problem to make sure that our customers have clean, compliant and complete data available for advanced analytics.”
When developing MedTech solutions, compliance with different healthcare standards is also paramount, says Kelly, so that solutions can fit easily into existing healthcare environments. “No matter how innovative a new solution may be, if it cannot slot neatly into existing healthcare infrastructure and facilitate the sharing of data between different systems and solutions, adoption is likely to be low.”
Data privacy and security are further considerations, including data management and consent principles that give patients control over their own data. And because MedTech is a global industry, European General Data Protection Regulation (GDPR) and California Consumer Privacy Act (CCPA) concerns, such as who owns patient-generated data, must also be addressed. Standards compliance, with high levels of scalability, needs to be front of mind even if you start with a proof of concept.
Technologies like artificial intelligence (AI) and the Internet of Things are also introducing new cybersecurity challenges. To address these, regulators around the world are introducing stringent guidelines on cybersecurity as a distinct process within each stage of development, from R&D through to systematic identification of risks during practical usage.
Artificial Intelligence that improves with use
Meeting these challenges will create new opportunities for MedTech companies. With increased data volumes, data quality, and consumer trust, AI will become more reliable. Couple this with machine learning and you will get a virtuous cycle where the more practice AI algorithms get, the better they will become.
AI and machine learning are already proving themselves in maximising the effectiveness of high-value medical equipment. For example, Mercy Radiology in New Zealand, working with Ferrum AI, has deployed two AI algorithms which use machine learning to improve over time with use. Operating in a second read capacity for radiologists, the two use-cases are in lung nodules on CT scans and limb fractures on X-ray.
The algorithms have improved the quality of reporting and “there has been positive engagement from clinicians as well,” says Lloyd McCann, CEO of Mercy Radiology and Head of Digital Health for Healthcare Holdings Limited.
Ultimately, however, for MedTech companies to seize the opportunities afforded by healthcare data, they must not only be able to handle increasing volumes and types of data, and deal with privacy and security concerns, but ensure that data is fit for purpose.
The success of data innovations based on AI and machine learning in particular will succeed or fail on the quality of the data that is used, and that makes the choice of data platforms that manage it a critical business decision.
About InterSystems
Established in 1978, InterSystems is the leading provider of data technology for extremely critical data in the healthcare, finance and logistics sectors. Its cloud-first data platforms solve interoperability, speed and scalability problems for large organisations around the globe. For more information, please visit InterSystems.com/au.
News & Trends - MedTech & Diagnostics
APAC medtech company scores TGA approval in heart disease
MedTech & Diagnostics News: An Asia Pacific medtech company has announced that its flagship drug-eluting stent (DES) has received regulatory […]
MoreNews & Trends - MedTech & Diagnostics
New state-based pilot to back home-grown medtech innovation
MedTech & Diagnostics: In a bid to enhance opportunities for local medtech manufacturers to sell to health services, a connected […]
MoreNews & Trends - Pharmaceuticals
Ferring unveils first real-world evidence for faecal calprotectin approach in ulcerative colitis
Pharma News: Ferring Pharmaceuticals has announced results from a new study, which provides the first real-world evidence supporting the efficacy […]
MoreNews & Trends - Pharmaceuticals
Bayer partners with RACGP, calls for MBS reforms to boost access to long-acting contraceptives
Pharma News: Australian women are calling for more accurate information about their contraceptive options, with 70% feeling inadequately educated about […]
More